Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Apr 20;61(4):2300270.
doi: 10.1183/13993003.00270-2023. Print 2023 Apr.

A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet

Mattia Nigro  1   2 , James D Chalmers  3 , Stefano Aliberti  4   2
Affiliations
Editorial

A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet

Mattia Nigro et al. Eur Respir J. .

Abstract

Other steroids are currently not superior to dexamethasone 6 mg in COVID-19 patients with acute respiratory failure https://bit.ly/3YUkc8G

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: M. Nigro has nothing to disclose. J.D. Chalmers has received research grants from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Gilead Sciences, Grifols, Novartis, Insmed and Trudell, and received consultancy or speaker fees from Antabio, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Insmed, Janssen, Novartis, Pfizer, Trudell and Zambon. S. Aliberti reports grants from Insmed Incorporated, Chiesi and Fisher & Paykel, royalties from McGraw Hill, consulting fees from Insmed Incorporated, Insmed Italy, Insmed Ireland Ltd, Zambon, AstraZeneca UK Limited, AstraZeneca Pharmaceutical LP, CSL Behring GmbH, Grifols, Fondazione Charta, Boehringer Ingelheim, Chiesi Farmaceutici Spa, ZCUBE Srl, Menarini, MSD Italia Srl, Physioassist SAS and GlaxoSmithKline Spa, lecture honoraria from GlaxoSmithKline Spa, Thermofisher Scientific, Insmed Italy, Insmed Ireland Ltd, Zambon and Fondazione Internazionale Menarini, and advisory board membership for Insmed Incorporated, Insmed Italy, AstraZeneca UK Limited and MSD Italia Srl, outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Forest plots showing: a) effects of other steroidal regimens (including higher doses of dexamethasone) over dexamethasone 6 mg on 28-day mortality in hospitalised patients with acute respiratory failure (ARF) due to COVID-19; b) effects of methylprednisolone regimens over dexamethasone 6 mg on 28-day mortality in hospitalised patients with ARF due to COVID-19; and c) effects of higher doses of dexamethasone over dexamethasone 6 mg on 28-day mortality in hospitalised patients with ARF due to COVID-19.
See this image and copyright information in PMC

Comment on

  • Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS).
    Salton F, Confalonieri P, Centanni S, Mondoni M, Petrosillo N, Bonfanti P, Lapadula G, Lacedonia D, Voza A, Carpenè N, Montico M, Reccardini N, Meduri GU, Ruaro B; MEDEAS Collaborative Group; Confalonieri M; MEDEAS Collaborative Group; Citton GM, Lapadula G, Bozzi C, Tavano S, Pozzan R, Andrisano AG, Jaber M, Mari M, Trotta L, Mondini L, Barbieri M, Ruggero L, Antonaglia C, Soave S, Torregiani C, Bogatec T, Baccelli A, Nalesso G, Re B, Pavesi S, Barbaro MPF, Giuliani A, Ravaglia C, Poletti V, Scala R, Guidelli L, Golfi N, Vianello A, Achille A, Lucernoni P, Gaccione AT, Romagnoli M, Fraccaro A, Malacchini N, Malerba M, Ragnoli B, Zamparelli AS, Bocchino M, Blasi F, Spotti M, Miele C, Piedepalumbo F, Barone I, Baglioni S, Dodaj M, Franco C, Andrani F, Mangia A, Mancini A, Carrozzi L, Rafanelli A, Casto E, Rogliani P, Ora J, Carpagnano GE, Di Lecce V, Tamburrini M, Papi A, Contoli M, Luzzati R, Zatta M, Di Bella S, Caraffa E, Francisci D, Tosti A, Pallotto C, De Rosa FG, Pecori A, Franceschini M, Carlin M, Orsini V, Spolti A, Inannace M, Santantonio T, Meli R, Sauro S, Fedeli C, Mangini E, Biolo G, Nunnari A, Pietrangelo A, Corradini E, Bocchi D, Boarini C, Zucchetto A, Lanini S. Salton F, et al. Eur Respir J. 2023 Apr 20;61(4):2201514. doi: 10.1183/13993003.01514-2022. Print 2023 Apr. Eur Respir J. 2023. PMID: 36356972 Free PMC article. Clinical Trial.

References

    1. World Health Organization . WHO COVID-19 Dashboard. https://covid19.who.int
    1. Huang C, Wang Y, Li X,et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. doi:10.1016/S0140-6736(20)30183-5 - DOI - PMC - PubMed
    1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med 2020; 383: 2255–2273. doi:10.1056/NEJMra2026131 - DOI - PMC - PubMed
    1. The RECOVERY Collaborative Group . Dexamethasone in hospitalized patients with Covid-19. N Engl J Med 2021; 384: 693–704. doi:10.1056/NEJMoa2021436 - DOI - PMC - PubMed
    1. Chalmers JD, Crichton ML, Goeminne PC,et al. . Management of hospitalised adults with coronavirus disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J 2021; 57: 2100048. doi:10.1183/13993003.00048-2021 - DOI - PMC - PubMed